Stories

A decline in young people smoking should be treated as good news — and as a reason to look carefully at what is changing. Falling smoking rates suggest that newer nicotine patterns do not automatically translate into more cigarette use, which challenges one of the strongest arguments against harm reduction. The priority now should be keeping youth smoking low while ensuring adult smokers are not denied lower-risk routes away from combustion. Policy should follow the trend, not the fear that the trend contradicts.

The evidence base for nicotine pouches is becoming harder to dismiss as a niche issue. As smoke-free, non-combustible products, pouches may offer adult smokers another route away from cigarettes, particularly where acceptability and everyday use matter. Their role should be assessed through toxicology, switching behaviour and population-level impact rather than moral discomfort with nicotine. A credible tobacco policy should ask whether these products reduce exposure to the harms of smoking — and regulate them accordingly.

Cancer prevention depends on identifying the exposures that drive disease burden. In tobacco use, the principal risk arises from combustion and the resulting toxicants, rather than nicotine itself. Conflating nicotine with smoking can weaken public understanding of relative risk and obscure the potential role of smoke-free alternatives for adults who continue to smoke. Public health communication should distinguish clearly between dependence, exposure and disease causation.

A claim from the top of government can shape what thousands of smokers believe about risk. Describing vaping and cigarettes in a way that blurs their differences does not protect public health; it can make lower-risk choices look pointless. Researchers challenging the Irish PM’s statement should be taken seriously because risk communication has consequences. Political messages on nicotine need to be accurate, proportionate and clear about the far greater harms of combustion.

A signature can turn uncertainty into authority. That is why public health statements on nicotine deserve careful reading before names are added to them. Claims about vaping, pouches or other smoke-free products can influence policy, clinical advice and the choices smokers believe are available. Experts should sign only what reflects the evidence clearly — including the difference between nicotine use and the far greater harms of combustion.

Cardiovascular risk is one of the places where nicotine policy needs the most precision. New nicotine products should be assessed by what they do to exposure, biomarkers and real-world switching, not by assuming every product carries the same risk as smoking. Cigarettes remain uniquely harmful because combustion drives a major share of cardiovascular damage. The evidence debate should help smokers understand relative risk clearly, while still recognising uncertainty where the science is still developing.

Vaping policy should not depend on which party finds it useful in a campaign cycle. Adult smokers need clear information, legal lower-risk options and safeguards that keep products away from young people. Turning vaping into a partisan symbol risks flattening the evidence into slogans, whether the aim is tougher restriction or faster authorisation. The real test is simpler: does the policy reduce smoking-related harm while keeping the market accountable?